Mumbai: Novartis India Limited, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.
Novartis India will also continue to invest there, but with caution, Ranjit Shahani, who is also the managing director of the company, told reporters after the Supreme Court judgment.
Earlier on Monday, the court dismissed Novartis' petition seeking patent protection for cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.
Novartis India will also continue to invest there, but with caution, Ranjit Shahani, who is also the managing director of the company, told reporters after the Supreme Court judgment.
Earlier on Monday, the court dismissed Novartis' petition seeking patent protection for cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.
© Thomson Reuters 2013
COMMENTS
Advertisement
Pak-Origin Man, Involved In 26/11 Terror Attack, Extraditable To India: US Court Video: Woman Tries To Jump Off Mumbai's Atal Setu, Saved By Driver, Cops "Unless It Defeats Ends Of Justice...": Supreme Court On Denying Bail To Juvenile Karnataka Chief Minister Siddaramaiah To Be Prosecuted In Land Scam Case LIVE: CBI Team At Kolkata Hospital For Digital Mapping Of Crime Scene Kolkata Rape-Murder: 5 Demands Of Doctors On 24-Hour Nationwide Strike Viral Video: Bird 'Unfurls' Flag In Kerala, Here's What Really Happened Olympic Medals or Kota Factory? Time to Let Young Minds Choose Is 'Wokeness' Killing Comedy - Or Are Ageing Comedians Crying Wolf? Track Latest News Live on NDTV.com and get news updates from India and around the world.